Dr Quaratino is an R&D executive with over 20 years' experience in clinical development and immunology research. She is Chief Medical Officer at Kymab, a clinical-stage biopharmaceutical company recently acquired by Sanofi with a deal value of approx. USD 1.5bn. She is also the Chair of the Scientific and Clinical Advisory Board for STipe Therapeutics. Prior to her role at Kymab, Dr Quaratino held a position as Global Clinical Program Leader - Translational Clinical Oncology at Novartis, responsible for the clinical development of proprietary therapeutic antibody programs in immuno-oncology. Prior to this, Dr Quaratino was Senior Medical Director and Immunology Advisor at Merck Serono, where she was responsible for the clinical development of various immunomodulators.

Dr Quaratino has an extensive professional background which includes a Medical Degree and a Doctorate in Hematology-Oncology from the University of Palermo, Italy and a PhD in Immunology from Imperial College London, UK. For a number of years, she was a Professor of Immunology at the University of Southampton, a leading institution for innovative research. During Dr Quaratino's time in Southampton her focus was on the pathogenic mechanisms underlying chronic inflammatory diseases and the interface between autoimmunity and cancer.

Chairman of the Nomination Committee, Mr. Ludvik Sandnes says: "We are very pleased to have attracted Dr Quaratino as new member of the Board. Dr Quaratino has an impressive track record in clinical development and immunology research. In its current phase of development, Targovax requires international competence on all levels. Dr Quaratino brings both experience from big pharmaceutical companies as well as a clinical-stage development company. Her research background is also of great interest to us, as it supplements the knowledge base in the Board."

Dr Quaratino is replacing Dr Wheeler. Targovax expresses the company's gratitude for the excellent work Dr Wheeler has done as member of the Board over the past years.